O Web version on PubMed Central for supplementary material.J Proteomics. Author manuscript; obtainable in PMC 2014 August 26.Tang et al.PageAcknowledgmentsThis function was supported by National Institutes of Wellness grant CA131582 to D.W.S., an institutional grant towards the Wistar Institute (NCI Cancer Core Grant CA010815), along with the Reproductive Scientist Improvement Program (NIH grant 5K12HD00849). We gratefully acknowledge the usage of the Wistar Institute Proteomics Core Facility and Dr. Dionyssios Katsaros, University of Turin, Turin, Italy, for giving patient serum specimens. We gratefully acknowledge the administrative assistance of Mea Fuller.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript
OncologistTheClinical Trial ResultsBladder Preservation Therapy for Muscle-Invading Bladder Cancers on Radiation Therapy Oncology Group Trials 8802, 8903, 9506, and 9706: Vascular Endothelial Development Element B Overexpression Predicts for Elevated Distant Metastasis and Shorter SurvivalTIM LAUTENSCHLAEGER,a ASHA GEORGE,b ALEXANDER C. KLIMOWICZ,c JASON A. EFSTATHIOU,d CHIN-LEE WU,e HOWARD SANDLER,g WILLIAM U. SHIPLEY,f WILLIAM J. TESTER,h MICHAEL P. HAGAN,i ANTHONY M. MAGLIOCCO,j ARNAB CHAKRAVARTIaDepartment of Radiation Oncology, Wexner Healthcare Center, Ohio State University, Columbus, Ohio, USA; bStatistical Center, Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania, USA; cFunctional Tissue Imaging Unit, Translational Investigation Laboratory, University of Calgary, Calgary, Alberta, Canada; dClark Center for Radiation Oncology, eUrology Study Laboratory, and f Genitourinary Oncology Unit; Massachusetts Basic Hospital, Boston, Massachusetts, USA; gDepartment of Radiation Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Healthcare Center, Los Angeles, California, USA; hDivision of Healthcare Oncology, Einstein Medical Center, Philadelphia, Pennsylvania, USA; iDepartment of Radiation Oncology, Health-related College of Virginia, Richmond, Virginia, USA; jDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center and Study Institute, Tampa, Florida, USA Access the complete final results of this trial and study all published Clinical Trial Outcomes at http://clinicaltrialresults.theoncologist/search/resultsaAUTHOR SUMMARY ABSTRACTBackground. From 1988 to 1999, the Radiation Therapy Oncology Group (RTOG) carried out 4 prospective studies (8802, 8903, 9506, 9706) of sufferers with clinical stage T24a muscle-invasive bladder cancer. Treatment was selective bladder preservation using transurethral surgery (TURBT) plus cisplatin-based induction and consolidation chemoradiation regimens, reserving radical cystectomy for invasive tumor recurrence. We investigated vascular endothelial development factor (VEGF) pathway biomarkers within this one of a kind clinical dataset (median follow-up of 3.Simvastatin 1 years).Gevokizumab Strategies.PMID:23937941 A total of 43 sufferers with tissue accessible from the entry TURBT have been included in this evaluation. Expression of VEGF ligands and receptors have been quantified and scored by the AQUA platform (HistoRX, now Genoptix, Carlsbad, CA) and analyzed after median split. Benefits. VEGF expression levels were not connected with elevated prices of comprehensive response to induction chemoradiation. Greater levels of cytoplasmic VEGF-B, VEGF-C, and VEGF-R2 have been connected with decreased overall survival rates. The 3-year overall survival estimates for higher and low expressers had been 43.7 and 75 for VEGF-B cytoplasm (p .01), 40.2 and 86.7 f.
